-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGN-193408 SR in Ocular Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGN-193408 SR in Ocular Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGN-193408 SR in Ocular Hypertension Drug Details: AGN-193408 SR is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Relapsed Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-2001 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-2001 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-2001 in Refractory Multiple Myeloma Drug Details: ISB-2001 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1302 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1302 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ISB-1302 in...
-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-3 in Fibrosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RP-3 in Fibrosarcoma Drug Details: RP-3 is under development for the treatment of advanced solid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ISB-1442 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1442 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISB-1442 in Relapsed Multiple Myeloma Drug Details: ISB-1442 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mometasone Furoate in Rhinosinusitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mometasone Furoate in Rhinosinusitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Mometasone Furoate in Rhinosinusitis Drug Details:LYR-210 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ISB-1442 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1442 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISB-1442 in Refractory Multiple Myeloma Drug Details: ISB-1442 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISB-1342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISB-1342 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISB-1342 in Solid Tumor Drug Details:ISB-1342 (GBR-1342) is under development for the treatment...